Federal Register / Vol. 70, No. 25 / Tuesday, February 8, 2005 / Notices 6707

six WD40 repeats, and a heparin- constitute a clearly unwarranted Place: Wyndham City Center Hotel, 1143 binding domain. In vitro, over invasion of personal privacy. New Hampshire Ave., NW., Washington, DC expression of AAMP–1 promotes tumor 20037. Name of Committee: National Cancer Contact Person: David E. Maslow, PhD, cell invasion and metastasis as well as Institute Special Emphasis Panel, RFA CA– angiogenesis. AAMP–1 was later found Chief, Resources and Training Review 05–002 and CA–05–006–IMAT. Branch, Division of Extramural Activities, to be over expressed in endothelial Date: March 9–10, 2005. National Cancer Institute, National Institutes cells, cytotrophoblasts, and poorly Time: 8 a.m. to 5 p.m. of Health, 6116 Executive Boulevard—Room differentiated colon Agenda: To review and evaluate grant 8117, Bethesda, MD 20892–7405, (301) 496– cells found in lymphatics. In addition, applications. 2330. Place: Gaithersburg Hilton, 620 Perry expression studies have shown (Catalogue of Federal Domestic Assistance Parkway, Gaithersburg, MD 20877. that AAMP–1 is over expressed in breast Program Nos. 93.392, Cancer Construction; Contact Person: Sherwood Githens, PhD, 93.393, Cancer Cause and Prevention and gastrointestinal tumors. Scientific Review Administrator, Special Research; 93.394, Cancer Detection and The issued patents claim , Review and Logistics Branch, National polypeptides, and recombinant Diagnosis Research; 93.395, Cancer Cancer Institute, Division of Extramural Treatment Research; 93.396, Cancer Biology polyclonal specific to Activities, 6116 Executives Blvd., Bethesda, Research; 93.397, Cancer Centers Support; AAMP–1 and their use in diagnostic MD 20892, 301/435–1822, 93.398, Cancer Research Manpower; 93.399, and therapeutic applications. The [email protected]. Cancer Control, National Institutes of Health, antibodies are specific and can detect (Catalogue of Federal Domestic Assistance HHS) Program Nos. 93.392, Cancer Construction; formalin-fixed antigen and SDS- Dated: February 2, 2005. denatured antigen. 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and LaVerne Y. Stringfield, These antibodies can be used for Diagnosis Research; 93.395, Cancer Director, Office of Federal Advisory detailed expression studies of AAMP–1 Treatment Research; 93.396, Cancer Biology Committee Policy. in different cancer cell lines. The Research; 93.397, Cancer Centers Support; [FR Doc. 05–2350 Filed 2–7–05; 8:45 am] antibodies could also be used to 93.398, Cancer Research Manpower; 93.399, BILLING CODE 4140–01–M promote cell adhesion to a substrate, Cancer Control, National Institutes of Health, promote tissue acceptance of prostheses, HHS) and promote wound healing. The Dated: February 2, 2005. DEPARTMENT OF HEALTH AND antibodies could also be used to detect LaVerne Y. Stringfield, HUMAN SERVICES AAMP–1 in patient’s sera as a useful Director, Office of Federal Advisory diagnostic marker for multiple Committees Policy. National Institutes of Health including high nuclear [FR Doc. 05–2349 Filed 2–7–05; 8:45 am] grade ductal in situ (Clinical National Cancer Institute; Notice of Cancer Research Dec 2002 8:3788–95). BILLING CODE 4140–01–M Closed Meeting Dated: January 31, 2005. Pursuant to section 10(d) of the DEPARTMENT OF HEALTH AND Steven M. Ferguson, Federal Advisory Committee Act, as HUMAN SERVICES Director, Division of Technology Development amended (5 U.S.C. Appendix 2), notice and Transfer, Office of Technology Transfer, is hereby given of the following National Institutes of Health. National Institutes of Health meeting. [FR Doc. 05–2394 Filed 2–7–05; 8:45 am] National Cancer Institute; Notice of BILLING CODE 4140–01–P The meeting will be closed to the Closed Meeting public in accordance with the provisions set forth in sections DEPARTMENT OF HEALTH AND Pursuant to section 10(d) of the 552b(c)(4) and 552b(c)(6), title 5 U.S.C., HUMAN SERVICES Federal Advisory Committee Act, as as amended. The grant applications and amended (5 U.S.C. Appendix 2), notice the discussions could disclose National Institutes of Health is hereby given of the following confidential trade secrets or commercial meeting. property such as patentable material, National Cancer Institute; Notice of The meeting will be closed to the and personal information concerning Closed Meeting public in accordance with the individuals associated with the grant applications, the disclosure of which Pursuant to section 10(d) of the provisions set forth in sections would constitute a clearly unwarranted Federal Advisory Committee Act, as 552b(c)(4) and 552b(c)(6), title 5 U.S.C., invasion of personal privacy. amended (5 U.S.C. Appendix 2), notice as amended. The grant applications and is hereby given of the following the discussions could disclose Name of Committee: National Cancer meeting. confidential trade secrets or commercial Institute Special Emphasis Panel property such as patentable material, Transdiciplinary Research on Energetics and The meeting will be closed to the and personal information concerning Cancer. public in accordance with the individuals associated with the grant Date: March 2–3, 2005. provisions set forth in sections applications, the disclosure of which Time: 8 a.m. to 6 p.m. 552b(c)(4) and 552b(c)(6), title 5 U.S.C., would constitute a clearly unwarranted Agenda: To review and evaluate grant applications. as amended. The grant applications invasion of personal privacy. and/or contract proposals and the Place: Holiday Inn Select Bethesda, 8120 discussions could disclose confidential Name of Committee: National Cancer Wisconsin Ave., Bethesda, MD 20814. trade secrets or commercial property Institute Special Emphasis Panel Special Contact Person: Mary Jane Slesinski, PhD, Emphasis Panel or Review of R25 Scientific Review Administrator, Special such as patentable material, and Applications. Review and Resources Branch, Division of personal information concerning Date: March 30–31, 2005. Extramural Activities, National Cancer individuals associated with the grant Time: 6 p.m. to 5 p.m. Institute, National Institutes of Health, 6116 applications and/or contract proposals, Agenda: To review and evaluate grant Executive Boulevard, Room 8045, Bethesda, the disclosure of which would applications. MD 20892, 301/594–1566.

VerDate jul<14>2003 20:29 Feb 07, 2005 Jkt 205001 PO 00000 Frm 00096 Fmt 4703 Sfmt 4703 E:\FR\FM\08FEN1.SGM 08FEN1